Cannabis Investors: Should You Buy Cronos (TSX:CRON) Stock Right Now?

Why investors are better off avoiding cannabis giant Cronos Group (TSX:CRON).

| More on:
tech and analysis

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more

Shares of marijuana giant Cronos Group (TSX:CRON)(NASDAQ:CRON) are trading at $7.56, which is 38% below its 52-week high and 75% below its record high. Despite the recent weakness, Cronos stock has returned 822% since its IPO back in December 2014. This means Cronos stock rose a staggering 3,600% between December 2014 and March 2019.

But we know past returns don’t matter much to current and future investors. What they need to know is if the stock is positioned to outperform peers and the broader markets in the upcoming decade.

Cronos stock is trading at a premium

In the June quarter, Cronos Group reported sales of $9.9 million, up 29% year-over-year. This is significantly lower than net sales of peers Canopy Growth and Aphria that reported revenue figures of $152 million and $110 million respectively, in their most recent quarters.

This also shows Cronos is trading at a hefty premium compared to industry peers. Cronos has a market cap of $2.65 billion indicating a forward price to sales multiple of 64. Comparatively, Aphria, and Canopy are trading at a forward price to sales multiple of 3.2 and 23 respectively.

One of the primary reasons for the stock’s sky-high valuation is the investment of Altria. The tobacco behemoth has a 45% stake in Cronos and pumped in $2.4 billion into the firm last March. This investment provides Cronos with access to liquidity as well as Altria’s expertise that can be leveraged to enter the high-growth vaping segment.

Last year, Cronos CEO Mike Gorenstein said, “We know the vaporizer space is one of the fastest-growing and evolving categories, with many consumers migrating to this convenient, noncombustible consumption method. At the same time, the category remains in its infancy with few products that are specifically tailored for cannabinoids.”

However, there are multiple players who have entered the marijuana vaping segment, including Canopy and Aphria. Further, the health concerns related to vaping might put a dampener on sales — at least in the near-term — as Canadian provinces of Quebec and Newfoundland and Labrador have banned vape sales.

What next for investors?

Cronos ended the June quarter with a cash balance of $1.3 billion, indicating that it has enough liquidity to tide over the macro-economic volatility. Alternatively, its operating cash flow stands at a negative $150 million in the last 12 months and its earnings loss might not inspire much confidence.

Cronos reported an operating loss of $21.3 million in 2018, and this figure ballooned to $121.5 million in 2019. In the first six months of 2020, its operating loss inched closer to $80 million, compared to sales of just $18.3 million in this period.

We can see that the road ahead for Cronos Group investors is rocky given structural issues surrounding the company. While Cronos is investing in derivatives products, there are research reports suggesting that edible product sales were flat while the demand for cannabis flower experienced an uptick in the second quarter.

Does this mean that consumers prefer lower-priced cannabis flowers compared to derivatives and edibles? If so, it brings bad news for Cronos investors, as it has a comparatively lower presence in flower production.

Cronos’ massive losses and high valuation metrics suggest investors would be wise to stay away from a stock that is struggling on multiple fronts.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Aditya Raghunath has no position in any of the stocks mentioned.

More on Cannabis Stocks

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Canopy Growth Stock: The Only Cannabis Stock to Consider Long Term

The cannabis stock industry remains an incredibly high risk one, but Canopy Growth (TSX:WEED)(NYSE:CGC) stock provides the best opportunity for…

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Should You Stay Away From HEXO Stock?

HEXO (TSX:HEXO)(NASDAQ:HEXO) stock is on a downward spiral, and there is little hope it is going to recover soon.

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Why Did Aurora Cannabis (TSX:ACB) Stock Plunge 75% in 2022?

A prominent cannabis stock has plunged by 75% in 2022, as the company’s losses continue to mount in the face…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Fire & Flower: A Small Pot Stock Poised for Strong Growth

Fire & Flower is a cannabis retailer well-positioned for growth thanks to its digital and delivery initiatives.

Read more »

edit Jars of marijuana
Cannabis Stocks

Why Aurora Cannabis (TSX:ACB) Stock Is Sinking This Week

Starting another round of capital raising has hurt investor sentiments, and the Canadian cannabis giant’s performance on the stock market…

Read more »

edit Jars of marijuana
Cannabis Stocks

Why Canopy Growth (TSX:WEED) Stock Plunged 19% Last Week

Canopy Growth Corp. (TSX:WEED)(NASDAQ:CGC) stock has plunged after the release of its final fiscal 2022 results.

Read more »

Cannabis stocks have fallen.
Cannabis Stocks

Why Aurora Cannabis (TSX:ACB) Stock Tanked 45% Last Week

There's no respite for Aurora Cannabis investors!

Read more »

Money growing in soil , Business success concept.
Cannabis Stocks

TFSA Investors: This Undervalued Gem Could Turn $6,000 Into $25,000

Here's why TFSA investors can hold undervalued growth stocks such as Verano in their portfolios right now.

Read more »